Can-Fite BioPharma Ltd. Stock
-
Your prediction
Can-Fite BioPharma Ltd. Stock
Pros and Cons of Can-Fite BioPharma Ltd. in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Can-Fite Biopharma Ltd.'s financials at a first glance appear to raise concerns due to some negative trends observable in certain metrics. However, a deeper analysis is required to fully comprehend the financial health of the company and identify potential pros and cons.
Cash and Short-term Investments: On a positive note, Can-Fite Biopharma Ltd. has a notable amount of cash and short-term investments. As of the end of 2022, the company has $7,987,000 in cash and short-term investments. This strong cash position could be a major advantage when it comes to facing financial challenges or making strategic investments.
Net working capital: Another positive aspect of the company is its net working capital, which stands at $6,655,000. This highlights the company's ability to cover its short-term liabilities with its short-term assets, enhancing its financial stability.